-
2025-522782-30-00
3
2026-04-07
CCI
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2025-520902-37-00
4
2026-04-01
Non-small cell lung cancer stage IV
-
2025-521730-28-00
4
2026-03-30
Colorectal Cancer with Cancer Cachexia
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2025-521858-42-00
5
2026-03-16
Hemophilia
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2024-513911-28-00
10
2026-03-04
Acute Ischemic Stroke
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2025-523202-32-00
5
2026-02-26
Major Depressive Disorder
-
2024-520098-12-00
4
2026-02-16
Cutaneous Lupus Erythematosus
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2024-518840-18-00
5
2025-12-10
Varicella
-
2024-512029-10-00
5
2025-12-05
Intermediate risk, non-muscle invasive bladder cancer
-
2025-521268-37-00
6
2025-11-25
Respiratory tract diseases
-
2025-520746-30-00
5
2025-11-18
Mild to moderate Alzheimer’s Disease
-
2025-521315-39-00
1
2025-11-05
Axial spondyloarthritis
-
2024-519623-23-00
5
2025-10-20
Venous leg ulcer
-
2024-519343-15-00
5
2025-10-08
Low-grade Upper Tract Urothelial Cancer
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P